Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IQVIA Holdings | Milan | Healthcare | Biotechnology & Medical Research | €24.29B | 22x | 79.44 | €139.15 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.98B | 111.5x | -1.53 | €41.61 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.32B | -6.3x | 0.05 | €7.40 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Milan | Healthcare | Biotechnology & Medical Research | €1.05B | 5.8x | 0.04 | €4.67 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Philogen SpA | Milan | Healthcare | Biotechnology & Medical Research | €907.47M | 18.8x | 0.02 | €22.50 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ | |
Arterra Bio | Milan | Healthcare | Biotechnology & Medical Research | €17.98M | 12.8x | 0.58 | €2.70 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ulisse Biomed Spa | Milan | Healthcare | Biotechnology & Medical Research | €17.68M | -3.4x | 0.33 | €0.72 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.4% Upside | Upgrade to Pro+ |